Inflarx Nv stock is traded at $1.18, with a volume of 577,514. It is down -2.48% in the last 24 hours and down -25.79% over the past month. InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Previous Close:
$1.21
Open:
$1.30
24h Volume:
577,514
Relative Volume:
0.43
Market Cap:
$173.89M
Revenue:
$72,500
Net Income/Loss:
-$45.96M
P/E Ratio:
-
EPS:
-$0.6814
Net Cash Flow:
-$44.56M
1W Performance:
-12.92%
1M Performance:
-25.79%
6M Performance:
-51.44%
1Y Performance:
-19.18%
1-Day Range:
$1.17$1.30
1-Week Range:
$1.17$1.40
52-Week Range:
$0.7984$2.95
Inflarx Nv Stock (IFRX) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS